Théa

European Investment Bank provides €150 million to Théa

The European Investment Bank provides €150 million in financing to Théa to accelerate ophthalmology R&D programmes and support industrial investments in Europe.

  • The financing agreement will support the Group’s research and development investments in Europe.
  • The project got the backing of the European Commission’s programme InvestEU.

This is the second loan granted by the EIB to Théa, following an initial loan of €50 million signed in 2021. This new transaction demonstrates the European institution’s renewed confidence in the Group’s strategy and in its ability, on the one hand, to transform scientific innovation into new therapeutic solutions for the benefit of patients and, on the other hand, to expand its European industrial capacity and secure supplies whilst complying with existing and future European standards.

It will support the Group’s investments in the development of new molecules, new formulations and innovative drug delivery systems for ophthalmic use.

As Europe’s leading independent ophthalmology company, Théa dedicates more than 12 per cent of its turnover to research and innovation every year. This funding will support several strategic R&D programmes, particularly in the fields of retinal diseases, rare inherited eye diseases, glaucoma and dry eye, with a view to accelerating the development of treatments to address medical needs that are currently unmet or inadequately met.

By supporting Théa’s R&D activities and industrial investments, the EIB is also helping to create and maintain scientific knowledge, expertise and highly skilled jobs in Europe. The project is in line with European priorities for technological innovation and biotechnology and is expected to benefit from the InvestEU guarantee, given the nature of the investments being financed.

Ambroise Fayolle, Vice-President of the European Investment Bank, said: “Following an initial €50 million financing package in 2021, this new €150 million loan opens a new chapter in our partnership with Théa. By supporting both the development of new therapies and the expansion of production capacity at this independent European leader in ophthalmology, the EIB is backing a vital ambition: to make Europe ever more innovative, competitive and sovereign in a sector as strategic as healthcare, for the benefit of patients.”

Jean-Frédéric Chibret, President of the Théa Group, said: “This second round of funding from the European Investment Bank represents an important milestone and a strong vote of confidence in our long-term strategy. For over thirty years, we have chosen to reinvest heavily in innovation to address medical needs that remain inadequately met. This funding will enable us to accelerate our R&D programmes and continue our industrial investments in Europe. It thus contributes to our ambition: to keep innovating to meet patients’ needs whilst strengthening our scientific and industrial capabilities in Europe.”

Founded in 1994 and still based in Clermont-Ferrand, Théa has built its growth on exclusive specialization in ophthalmology, a long-term vision and the consistent reinvestment of its profits in innovation. This strategy combines incremental innovation – through the continuous improvement of therapeutic solutions used on a daily basis by patients and healthcare professionals – with disruptive innovation, involving the development of new treatments in complex fields such as retinal and rare diseases.

This transaction forms part of an integrated model combining research, development and industrial capabilities in Europe. In particular, the EIB has recognized the strategic value of Théa’s investments in its industrial infrastructure, as is the case at the Milan industrial site, a cornerstone of the Group’s development.

Background information  

About the EIB Group   

The European Investment Bank (EIB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 high-impact projects under eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investments union. High-quality, up-to-date photos of our headquarters for media use are available here.

About InvestEU 

InvestEU brings together under one roof the many EU financial instruments to support a sustainable economy and mobilise private investment for the European Union’s strategic priorities, such as resilience, green and secure energy, competitiveness, and SME support. InvestEU makes financing in Europe simpler, more efficient, and more flexible. The InvestEU Fund, part of the InvestEU programme, is deployed through implementing partners, which invest in projects using an EU budget guarantee of €29.1 billion to increase their risk-bearing capacity. As a result, including further top-ups, the programme expects to mobilise at least €427 billion in additional investment. InvestEU exceeded its original target of €372 billion in the beginning of 2026.  

About Théa

Founded in Clermont-Ferrand in 1994, Théa is Europe’s leading independent ophthalmology company. A family-owned pharmaceutical group exclusively dedicated to eye health, it operates in over 75 countries through 35 subsidiaries and employs nearly 2,500 people. Théa develops and markets solutions covering the main eye conditions, from the anterior segment of the eye to retinal and rare diseases. Each year, the Group reinvests more than 12 per cent of its turnover (€1,020 million in 2025) in research and innovation.